Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

Background

Plexxikon accused Novartis of infringing specified claims of U.S. Patent Nos. 9,469,640 and 9,844,539. The patents claim a class of chemical compounds, including a fluorine atom in an “inner,” or second, position on a phenyl ring. The parties agreed that the position of the elements mattered and that a compound lacking the fluorine in that position would not satisfy the claims.

Novartis argued that the asserted claims were invalid as anticipated under 35 U.S.C. § 102 by two earlier references: U.S. Patent No. 4,595,780, called Shionogi, and PCT Patent Publication No. WO 06/124874, called the Kalypsys Application. The opinion states that both references predated the applications for the asserted patents by more than one year. Plexxikon sought summary judgment that neither reference anticipated the claims. The order states that the ruling was partial because Novartis asserted other anticipation grounds in the case, including in its own summary-judgment motion.

Legal standard

Summary judgment is appropriate when there is no genuine dispute about a material fact and the moving party is entitled to judgment as a matter of law. Anticipation is a patent-invalidity theory based on lack of novelty. It requires a single prior-art reference to disclose every limitation of the claimed invention, expressly or inherently, with the elements arranged as the claim requires.

A broad “genus”—a category covering many possible compounds—does not necessarily disclose every compound within it. It can anticipate a claimed species only when the genus is limited enough that a skilled person could immediately envision every member of the relevant class. A prior-art reference also cannot be treated as a catalogue from which separate teachings are freely selected and rearranged. Modifying or combining disclosures may support an obviousness argument, but it does not establish anticipation unless the reference clearly teaches the claimed combination and the possible combinations are sufficiently limited.

Shionogi

The court held that Shionogi’s broad Formula (I) did not anticipate the claims. The formula had five variables, with multiple options for each, creating at least hundreds of possible combinations. The court found that this was not a definite and limited class that would allow a skilled person to immediately envision every member.

The court also held that Shionogi’s Example 61 did not anticipate the claims because it lacked the required fluorine atom in the inner position of the phenyl ring. Novartis’s expert agreed that Example 61 met the claim limitations except for that missing fluorine.

The remaining issue was whether a person skilled in the field could combine Example 61 with the fluorine option in Formula (I). The court rejected that theory. It found that Example 61 was a complete and distinct embodiment, and that Shionogi did not teach combining its alternative elements into the claimed compound. The court also reasoned that substituting or adding the fluorine would modify Example 61, making the theory one of obviousness rather than anticipation. In addition, the expert acknowledged that Formula (I) offered perhaps hundreds of possible modifications, which made the claimed combination insufficiently immediate or apparent.

Kalypsys Application

The court found the anticipation argument based on the Kalypsys Application even weaker. Novartis’s expert agreed that Compound 132 did not fall within the asserted claims but opined that the application disclosed the modifications needed to make it meet the claims. The court treated that reasoning as modification, not anticipation.

The court also rejected the argument that a skilled person would immediately envision simplifying Compound 132 because the change might have advantages. The applicable inquiry asks whether a limited number of disclosed combination possibilities includes the claimed combination; it does not allow missing claim limitations to be supplied merely because a skilled person could envision them. Because the expert did not address the number or size of the possible combinations, his opinion did not create a genuine factual dispute.

Disposition

The court granted Plexxikon’s motion for summary judgment of no anticipation by Shionogi or the Kalypsys Application. The opinion’s conclusion states that disposition as applying to both references. One sentence in the Kalypsys section appears to repeat “Shionogi,” but the motion title, discussion, and conclusion make clear that the stated ruling covered both Shionogi and the Kalypsys Application.